Ludovica Iovino

Ludovica Iovino

Auto-generated profile, based on publicly available information

Ludovica Iovino

National Research Council (CNR), Institute of Neuroscience, Pisa, Italy ; Stella Maris Foundation, IRCCS, Calambrone, Pisa, Italy

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
EGElena Giusto
Elena Giusto
Lorenza MaistrelloLorenza Maistrello
Lorenza Maistrello
LILucia Iannotta
Lucia Iannotta
VGVeronica Giusti
Veronica Giusti
LILudovica Iovino
Ludovica Iovino
LCLaura Civiero
Laura Civiero
2. Background: Parkinson’s disease is a progressive neurodegenerative disorder mainly distinguished by sporadic aetiology, although a genetic component is also well established. Variants in the LRRK2 gene are associated with both familiar and sporadic disease. We have previously shown that PAK6 and 14-3-3γ protein interact with and regulate the activity of LRRK2. Objectives: The aim of this study is to quantify PAK6 and 14-3-3γ in plasma as a reliable biomarker strategy for the diagnosis of both sporadic and LRRK2-linked Parkinson’s disease. Methods: After an initial quantification of PAK6 and 14-3-3γ expression by means of Western blot in post-mortem human brains, we verified the presence of the two proteins in plasma by using quantitative ELISA tests. We analysed samples obtained from 39 healthy subjects, 40 patients with sporadic Parkinson’s disease, 50 LRRK2-G2019S non-manifesting carriers and 31 patients with LRRK2-G2019S Parkinson’s disease. Results: The amount of PAK6 and 14-3-3γ is significantly different in patients with Parkinson’s disease compared to healthy subjects. Moreover, the amount of PAK6 also varies with the presence of the G2019S mutation in the LRRK2 gene. Although the generalized linear models show a low association between the presence of PD and PAK6, the kinase can be added in a broader panel of biomarkers for the diagnosis of Parkinson’s disease. Conclusions: Changes of PAK6 and 14-3-3γ amount in plasma represent a shared readout for patients affected by sporadic and LRRK2-linked Parkinson’s disease. Overall, they can contribute to the establishment of an extended panel of biomarkers for the diagnosis of Parkinson’s disease.

5 August 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
LILudovica Iovino
Ludovica Iovino
VGVeronica Giusti
Veronica Giusti
FPFrancesca Pischedda
Francesca Pischedda
EGElena Giusto
Elena Giusto
Nicoletta PlotegherNicoletta Plotegher
Nicoletta Plotegher
LCLaura Civiero
Laura Civiero
The Excitatory Amino Acid Transporter 2 (EAAT2) accounts for 80 % of brain glutamate clearance and is mainly expressed in astrocytic perisynaptic processes. EAAT2 function is finely regulated by endocytic events, recycling to the plasma membrane and degradation. Noteworthy, deficits in EAAT2 have been associated with neuronal excitotoxicity and neurodegeneration. In this study, we show that EAAT2 trafficking is impaired by the leucine-rich repeat kinase 2 (LRRK2) pathogenic variant G2019S, a common cause of late-onset familial Parkinson’s disease (PD). In LRRK2 G2019S human brains and experimental animal models, EAAT2 protein levels are significantly decreased, which is associated with elevated gliosis. The decreased expression of the transporter correlates with its reduced functionality in mouse LRRK2 G2019S purified astrocytic terminals and in Xenopus laevis oocytes expressing human LRRK2 G2019S. In LRRK2 G2019S knockin mouse brain, the correct surface localization of the endogenous transporter is impaired, resulting in its interaction with a plethora of endo-vesicular proteins. Mechanistically, we report that pathogenic LRRK2 kinase activity delays the recycling of the transporter to the plasma membrane via Rabs inactivation, causing its intracellular relocalization and degradation. Taken together, our results demonstrate that pathogenic LRRK2 interferes with the physiology of EAAT2, pointing to extracellular glutamate overload as a possible contributor to neurodegeneration in PD.

5 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
VGVeronica Giusti
Veronica Giusti
JPJungjoo Park
Jungjoo Park
EGElena Giusto
Elena Giusto
LMLaura Masatti
Laura Masatti
PRP Ramos-Gonzalez
P Ramos-Gonzalez
LCLaura Civiero
Laura Civiero
Astrocytes participate in the clearance of obsolete or unwanted neuronal synapses. However, the molecular machinery involved in recognizing these synapses remains unclear, particularly under pathological conditions. Here, we investigated the phagocytic process of astrocytes through individual gene silencing with a druggable gene library. Our study demonstrates that astrocyte- mediated synapse engulfment is regulated by the Atypical chemokine receptor 3 (Ackr3). Mechanistically, we showed that Ackr3 recognizes phosphatidylethanolamine (PE)-bound C-X-C motif chemokine 12 (CXCL12) at synaptic terminals both in vitro and in vivo, thus serving as a novel marker of synaptic dysfunction. Notably, both the receptor and its ligand are upregulated in post- mortem human Alzheimer’s disease (AD) brains, and AD mouse models. Downregulation of the Ackr3 in AD mice significantly diminishes astrocyte-mediated synaptic elimination, and rescues pathological phenotypes, including synapse loss and cognitive impairment. Overall, this work unveils a novel, possibly targetable mechanism of astrocyte-mediated synaptic engulfment implicated in neurodegenerative disease.

23 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
LILudovica Iovino
Ludovica Iovino
JVJared VanderZwaag
Jared VanderZwaag
GKGurkirat Kaur
Gurkirat Kaur
PKParsa Khakpour
Parsa Khakpour
VGVeronica Giusti
Veronica Giusti
LCLaura Civiero
Laura Civiero
Microglia, the central nervous system resident immune cells, are now recognized to critically impact homeostasis maintenance and contribute to the outcomes of various pathological conditions including Parkinson’s disease (PD). Microglia are heterogenous, with a variety of states recently identified in aging and neurodegenerative disease models, including the ‘disease-associated microglia’ (DAM) which present a selective enrichment of CLEC7A encoding the CLEC7A or DECTIN1 protein, and the ‘dark microglia’ (DM) displaying markers of cellular stress at the ultrastructural level. However, the roles of CLEC7A-positive microglia and DM in the pathology of PD have remained largely elusive. By applying immunofluorescence and scanning electron microscopy, we aimed to characterize 1) the CLEC7A -positive cell population, and 2) their possible relationships to DM in a mouse model harboring a G2019S pathogenic mutation of the LRRK2 gene, the most common mutation linked to PD. We examined 18-month-old mice, comparing between LRRK2 G2019S knock-in mice and wild-type controls. In the dorsal striatum, a region affected by PD pathology, extensive ultrastructural features of cellular stress (e.g., endoplasmic reticulum and Golgi apparatus dilation), as well as reduced direct cellular contacts, were observed for microglia from LRRK2 G2019S mice versus controls. CLEC7A-positive microglia exhibited extensive phagocytic ultrastructural characteristics in the LRRK2 G2019S mice. Additionally, the LRRK2 G2019S mice presented a higher proportion of DM. Lastly, immunofluorescence and biochemical analysis revealed higher number of CLEC7A-positive cells in Lrrk2 G2019S genotype versus controls both in tissues and in primary microglia cells. Of note, CLEC7A-positive cells present a selective enrichment of ameboid morphology and tend to cluster in the pathogenic animal. In summary, we provide novel insights into the involvement of recently-defined microglial states, CLEC7A-positive cells and DM, in the context of LRRK2 G2019S PD pathology.

30 July 2025 in bioRxiv
Verified
Preprint
Open access
LBLuca Ballotto
Luca Ballotto
TBThomas Baratta
Thomas Baratta
HWHelena Winterberg
Helena Winterberg
CDCédric Dusanter
Cédric Dusanter
SSSara Sambin
Sara Sambin
SNSalvatore Novello
Salvatore Novello
Neuroinflammation is increasingly recognized as a central pathological mechanism in Parkinson’s disease (PD), a progressive neurodegenerative disorder characterized by the selective loss of dopaminergic neurons and variety of motor and non-motor symptoms. The NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome and its adaptor protein ASC play a critical role in initiating and maintaining inflammatory responses in the central nervous system. Although its acute activation is beneficial for host defense and homeostasis, chronic activation of the inflammasome has been associated with the pathogenesis of PD. Another key contributor to neuroinflammation is the leucine-rich repeat kinase 2 (LRRK2), particularly the G2019S mutation associated with PD, which has been shown to exacerbate inflammatory signaling in microglia and peripheral immune cells. However, the interaction between LRRK2 and the NLRP3 inflammasome pathway remains poorly understood. In this study, we investigated the role of LRRK2-G2019S in the priming and activation dynamics of the NLRP3 inflammasome using mouse primary microglia and human monocyte-derived microglia-like cells (hMDMi). We observed that LRRK2-G2019S microglia exhibit increased expression of NLRP3 under basal conditions and spontaneous formation of ASC specks within the nucleus, an unexpected subcellular location not previously reported in microglia. Interestingly, nuclear ASC specks also formed in wild-type microglia and hMDMi after lipopolysaccharide (LPS) priming but only progressed to cytosolic ASC specks and interleukin-1β release after subsequent exposure to canonical NLRP3 activators. These findings suggest that nuclear ASC specks may represent a primed state of inflammasome activation and propose a novel cellular phenotype associated with LRRK2-G2019S. Altogether, our results reveal a new layer of inflammasome regulation in microglia and implicate LRRK2-G2019S in the promotion of a pro-inflammatory state, which may predispose to chronic neuroinflammation in PD. These findings advance our understanding of glial immune regulation and highlight potential therapeutic targets in PD.